September 15, 2011

ACORDA THERAPEUTICS (ACOR): TIME TO TAKE PROFITS

It is time to take profits on Acorda Therapeutics (ACOR). Consider taking profits on the entire position of Acorda Therapeutics right here at $23.08.

Ampyra, the drug that has caused most excitement in Acora Therapeutics, is not proving to be a very good drug as we had predicted. Please see prior post on Acorda Therapeutics. However, this is company is highly promotional and periodically tends to release meaningless press releases that run the stock up.

The plan is to short Acorda Therapeutics again on any run up. A signal will be provided in real-time on the Real Time Feed of the ZYX Short Sell Change Alert.… Please click here or the title below to read more.

September 15, 2011

VIVUS (VVUS): INVESTORS MAY BE TOO OPTIMISTIC

Vivus (VVUS ) shares have moved up strongly on the news that FDA has agreed to an early re-submission of the QNEXA NDA for the treatment of obesity.

The road is not all clear for Vivus. There are still major issues that need to be resolved by Vivus including birth defect concerns, cardiovascular concerns, and epilepsy concerns.

If and when six screens of the ZYX Change Method are satisfied, we will issue a buy signal on the Real Time Feed of the ZYX Buy Change Alert.… Please click here or the title below to read more.

September 15, 2011

TAKING PARTIAL PROFITS ON PAN AMERICAN SILVER (PAAS)

We are taking partial profits on a 5% tranche of Pan American Silver (PAAS) at $31.82.… Please click here or the title below to read more.

September 15, 2011

TAKING PROFITS ON DEUTSCHE BANK (DB)

We are taking profits and exiting the Deutsche Bank (DB) position right here at $36.20.

We had not intended to exit Deutsche Bank position so quickly, but since we were fortunate to garner a large profit in a very short time, in this market environment it is prudent to book profits.… Please click here or the title below to read more.

September 15, 2011